ArticleAnimal models and experimental medicine2025
Establishment of a novel alloxan-induced rabbit model exhibiting unique diabetic retinal neuropathy features assessed via ERG + VEP.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tree shrew model of early diabetic retinopathy reveals microvascular dysfunction and identifies phosphoserine aminotransferase 1 as a novel therapeutic target.Animal models and experimental medicine · 2026Article
- Correlation Analysis of Lower Limb Contrast-Enhanced Ultrasound Findings With Serum VEGF and CXCL-12 Levels in a Rabbit Model of Diabetic Foot.BioMed research international · 2026Article
- Establishment of a novel alloxan-induced rabbit model exhibiting unique diabetic retinal neuropathy features assessed via ERG + VEP.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundDiabetic retinal neuropathy (DRN) leads to significant visual impairment; however, no existing animal model fully replicates its neural alterations, and inconsistent induction protocols with high mortality rates hinder long-term investigations.
methodsAdult male rabbits were randomly assigned to four experimental groups, each receiving a single intravenous injection of varying doses of alloxan and one control group. The safety and efficacy of alloxan in inducing diabetes were evaluated to determine the optimal dose. At 9 weeks following injection with alloxan, retinal function was assessed using full-field electroretinography (ERG) and visual evoked potentials (VEPs). Retinal structure was examined in rabbits using spectral-domain optical coherence tomography (SD-OCT), Optos ultra-widefield (Optos UWF) false-color imaging, and widefield fundus fluorescein angiography (WF-FFA).
resultsRabbits in the 80 mg/kg alloxan group exhibited fewer complications, lower mortality, and a higher model success rate compared to other groups. At 9 weeks post-injection, these rabbits demonstrated significantly elevated hemoglobin A1c and total cholesterol (p < 0.05) relative to controls. ERG revealed statistically significant reductions in oscillatory potential and b-wave amplitudes (p < 0.05), while VEP indicated decreased P2 amplitude (p < 0.001) and prolonged P2 latency (p < 0.05). SD-OCT, Optos UWF imaging, and WF-FFA demonstrated no significant changes in vascular abnormalities. Additionally, Hematoxylin and Eosin staining revealed retinal swelling (p < 0.05), and immunofluorescence confirmed glial activation and neuronal loss.
conclusionsA single intravenous injection of 80 mg/kg alloxan effectively and safely induced DRN in rabbits, resulting in neural retina damage, thereby establishing this model as an ideal model for DRN research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.